ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.

Apostolia M Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.